Large-scale interventional trials, such as weight reduction, intensive anti-GERD and anti-diabetes (especially thiazolidinedione which is known to increase serum adiponectin) drugs or combinations of these therapies, should be provided to assess the effects of appropriate treatment on the outcome of T2DM patients with GERD symptoms. The gene discussed is ADIPOQ; the disease is type 2 diabetes mellitus.